-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$16.751150% Upside
Nektar Therapeutics Frequently Asked Questions
-
What analysts cover Nektar Therapeutics?
Nektar Therapeutics has been rated by research analysts at Mizuho Securities, J.P. Morgan, Ladenburg Thalmann & Co., Goldman Sachs in the past 90 days.